## Updates

Follow [@iatlas_cri](https://twitter.com/iatlas_cri) on Twitter for latest developments!

## Source code and data resources
iAtlas app, tools, and data and annotations

+ **GitHub:** https://github.com/CRI-iAtlas
+ **GitLab:** https://gitlab.com/cri-iatlas
+ **iAtlas Notebooks:** https://github.com/CRI-iAtlas/iatlas-notebooks
+ **Synapse:** https://www.synapse.org/#!Synapse:syn10337516/wiki/458420
+ **Immune Subtype Classifier:** https://github.com/CRI-iAtlas/ImmuneSubtypeClassifier
+ **DockStore:** https://dockstore.org/organizations/SageBionetworks/collections/iatlas

### TCGA originating sources

+ **TCGA PanCancer Atlas:** https://gdc.cancer.gov/about-data/publications/pancanatlas
+ **Immune Landscape of Cancer Manuscript Page:** https://gdc.cancer.gov/about-data/publications/panimmune
+ **The Cancer Genome Atlas:** http://cancergenome.nih.gov/
+ **NCI Genomic Data Commons:** https://portal.gdc.cancer.gov/

### Source for targets of immunotherapy studies

+ **CRI Landscape of Immuno-Oncology Drug Development:** https://www.cancerresearch.org/scientists/immuno-oncology-landscape

### Source for data in the Molecular Response to Immune Checkpoint Inhibitor modules:

* [Choueiri et al. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016;22(22):5461-5471](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106340/)

* [Cloughesy et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 Mar;25(3):477-486](https://doi.org/10.1038/s41591-018-0337-7)

* [Gide et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell. 2019 Feb 11;35(2):238-255.e6](https://www.cell.com/cancer-cell/fulltext/S1535-6108(19\)30037-6)

* [Hugo et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016 Mar 24;165(1):35-44](https://www.cell.com/cell/fulltext/S0092-8674(16\)30215-X)

* [Kim et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018 Sep;24(9):1449-1458. doi: 10.1038/s41591-018-0101-z. Epub 2018 Jul 16. PMID: 30013197](https://pubmed.ncbi.nlm.nih.gov/30013197/)

* [Liu et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma [published correction appears in Nat Med. 2020 Jul;26(7):1147]. Nat Med. 2019;25(12):1916-1927](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898788/)

* [Mariathasan et al. TGFÎ² attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018 Feb 22;554(7693):544-548](https://doi.org/10.1038/nature25501)

* [McDermott et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med.  2018 Dec;24(12):1941. Nat Med. 2018;24(6):749-757](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721896/)

* [Miao et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035749/)

* [Riaz et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 2;171(4):934-949.e16](https://www.cell.com/cell/fulltext/S0092-8674(17\)31122-4)

* [Van Allen et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015 Oct 9;350(6257):207-211](https://pubmed.ncbi.nlm.nih.gov/26359337/)

* [Zhao et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma [published correction appears in Nat Med. 2019 Apr 17;:]. Nat Med. 2019;25(3):462-469](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810613/)

## Workflows
Workflows for characterization of immune environment in cancer

+ **CWL workflows:** https://github.com/CRI-iAtlas/iatlas-workflows
+ **Docker tools:** https://quay.io/organization/cri-iatlas

## Manuscripts

+ [Eddy et al. CRI iAtlas: an interactive portal for immuno-oncology research. F1000Research 2020, 9:1028](https://f1000research.com/articles/9-1028/v1)

+ [Gibbs DL, Robust classification of Immune Subtypes in Cancer, bioRxiv 2020.01.17.910950](https://www.biorxiv.org/content/10.1101/2020.01.17.910950v1)

+ [Saltz et al. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep. 2018 Apr 3;23(1):181-193.e7](https://www.cell.com/cell-reports/fulltext/S2211-1247(18\)30447-9)

+ [Sayaman et al. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021 Feb 9;54(2):367-386.e8](https://www.cell.com/immunity/fulltext/S1074-7613(21\)00034-0)

+ [Thorsson et al. The Immune Landscape of Cancer. Immunity. 2018 Apr 17;48(4):812-830.e14](https://www.cell.com/immunity/fulltext/S1074-7613(18\)30121-3)

+ [Upadhaya et al. Immuno-oncology drug development forges on despite COVID-19. Nat Rev Drug Discov. 2020 Nov;19(11):751-752](https://www.nature.com/articles/d41573-020-00166-1)

## Organizations
Organizations contributing to iAtlas

+ **Cancer Research Institute:** http://cancerresearch.org
+ **Sage Bionetworks:** http://www.sagebionetworks.org
+ **Institute for Systems Biology:** http://www.isbscience.org
+ **UNC Lineberger Comprehensive Cancer Center:** https://unclineberger.org
